Life sciences business signs significant contract

YORKSHIRE’S OptiBiotix Health, a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed an agreement with Nizo Food Research BV, the contract food research organisation in the Netherlands.
 
York-based OptiBiotix is contracting Nizo to undertake pre-clinical claims support for three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years.  These strains have shown an ability to reduce cholesterol by between 72% and 81% in laboratory studies.

Nizo, which is one of the most advanced, independent contract research companies in the world,  works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. Nizo has the largest food-grade pilot plant in Europe.
 
Stephen O’Hara, CEO of OptiBiotix, said: “Pre-clinical claims support is an important milestone in determining which of our three cholesterol reducing Lactobacillus strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies.

“We expect this work to be completed by the end of 2014 so we can commence human studies in early 2015.  This is consistent with our core strategy of creating products with a solid science base validated by human studies allowing us to build a successful and sustainable business for our customers and shareholders. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality.”

Click here to sign up to receive our new South West business news...
Close